Cholestech Looks To Capitalize On Possible OTC Switch For Cholesterol Drugs
This article was originally published in The Gray Sheet
Executive Summary
Cholestech is poised to ink a cosponsorship agreement with J&J/Merck for its Cholestech L.D.X. in vitro diagnostic should the drug partnership's Mevacor be cleared for over-the-counter use to reduce cholesterol.